{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:13:36Z","timestamp":1788779616659,"version":"build-2803163510"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To explore the expression pattern and functional role of EPH receptor A3 (EPHA3) in high-risk gastrointestinal stromal tumors (GISTs) and its potential relevance to tumor progression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      Immunohistochemical (IHC) analysis was performed to evaluate EPHA3 expression across a pilot cohort of clinical GIST specimens with different risk stratifications. The biological functions of EPHA3\n                      <jats:italic>in vitro<\/jats:italic>\n                      were assessed using (5-ethynyl-2\u2019-deoxyuridine, EdU) assay, colony formation, apoptosis, wound-healing, and transwell assays in EPHA3-knockout GIST-430 cells. Furthermore, RNA sequencing (RNA-seq) analysis was utilized to identify differentially expressed genes and associated signaling pathways following EPHA3 knockout.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      EPHA3 expression was found to be elevated in high-risk GIST specimens compared with intermediate-risk cases. Loss-of-function assays demonstrated that EPHA3 knockout attenuated cell proliferation and migration while promoting apoptosis\n                      <jats:italic>in vitro<\/jats:italic>\n                      . Pathway enrichment analysis suggested that EPHA3 expression is associated with cell adhesion, extracellular matrix interaction, and mesenchymal-related phenotypic remodeling.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings suggest that EPHA3 is upregulated in high-risk GIST and contributes to aggressive cellular behavior\n                      <jats:italic>in vitro<\/jats:italic>\n                      . These preliminary data indicate that EPHA3 may play a role in the malignant progression of GIST, although its clinical utility as a biomarker requires further validation in larger cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2026-0042","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:27Z","timestamp":1788778827000},"page":"416-426","source":"Crossref","is-referenced-by-count":0,"title":["EPHA3, upregulated in high-risk histological subtypes of gastrointestinal stromal tumor, promotes GIST progression"],"prefix":"10.2478","volume":"60","author":[{"given":"Han","family":"Wei","sequence":"first","affiliation":[{"name":"1 Department of Molecular Pharmacology, School of Medicine, Nankai University ; Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhao","sequence":"additional","affiliation":[{"name":"2 Department of General Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University , Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Wang","sequence":"additional","affiliation":[{"name":"1 Department of Molecular Pharmacology, School of Medicine, Nankai University ; Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Guo","sequence":"additional","affiliation":[{"name":"3 Institute of Digestive Disease, Shengli Oilfield Central Hospital , Dongying , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Liu","sequence":"additional","affiliation":[{"name":"2 Department of General Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University , Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuntao","family":"Wang","sequence":"additional","affiliation":[{"name":"2 Department of General Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University , Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Yang","sequence":"additional","affiliation":[{"name":"1 Department of Molecular Pharmacology, School of Medicine, Nankai University ; Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Qi","sequence":"additional","affiliation":[{"name":"1 Department of Molecular Pharmacology, School of Medicine, Nankai University ; Tianjin , , China"},{"name":"2 Department of General Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University , Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencong","family":"Tian","sequence":"additional","affiliation":[{"name":"2 Department of General Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University , Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"2 Department of General Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University, Nankai University , Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[{"name":"1 Department of Molecular Pharmacology, School of Medicine, Nankai University ; Tianjin , , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026090711002008813_j_raon-2026-0042_ref_001","doi-asserted-by":"crossref","unstructured":"Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-89. doi: 10.1097\/00000478-199904000-00002","DOI":"10.1097\/00000478-199904000-00002"},{"key":"2026090711002008813_j_raon-2026-0042_ref_002","doi-asserted-by":"crossref","unstructured":"Xu Y, Peng XL, East MP, Mccabe IC, Stroman GC, Jenner MR, et al. Tumorintrinsic kinome landscape of pancreatic cancer reveals new therapeutic approaches. Cancer Discov 2025; 15: 346-62. doi: 10.1158\/2159-8290.CD-23-1480","DOI":"10.1158\/2159-8290.CD-23-1480"},{"key":"2026090711002008813_j_raon-2026-0042_ref_003","doi-asserted-by":"crossref","unstructured":"Venkataraman V, George S, Cote GM. Molecular advances in the treatment of advanced gastrointestinal stromal tumor. Oncologist 2023; 28: 671-81. doi: 10.1093\/oncolo\/oyad167","DOI":"10.1093\/oncolo\/oyad167"},{"key":"2026090711002008813_j_raon-2026-0042_ref_004","doi-asserted-by":"crossref","unstructured":"Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45. doi: 10.1016\/S0022-3565(24)38879-2","DOI":"10.1016\/S0022-3565(24)38879-2"},{"key":"2026090711002008813_j_raon-2026-0042_ref_005","doi-asserted-by":"crossref","unstructured":"Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39: 1411-9. doi: 10.1016\/j.humpath.2008.06.025","DOI":"10.1016\/j.humpath.2008.06.025"},{"key":"2026090711002008813_j_raon-2026-0042_ref_006","doi-asserted-by":"crossref","unstructured":"Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012; 307: 1265-72. doi: 10.1001\/jama.2012.347","DOI":"10.1001\/jama.2012.347"},{"key":"2026090711002008813_j_raon-2026-0042_ref_007","doi-asserted-by":"crossref","unstructured":"Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology 2010; 57: 259-70. doi: 10.1111\/j.1365-2559.2010.03624.x","DOI":"10.1111\/j.1365-2559.2010.03624.x"},{"key":"2026090711002008813_j_raon-2026-0042_ref_008","doi-asserted-by":"crossref","unstructured":"Xi H, Wu X, Wei B, Chen L. Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival. J Gastroenterol 2012; 47: 785-94. doi: 10.1007\/s00535-012-0549-4","DOI":"10.1007\/s00535-012-0549-4"},{"key":"2026090711002008813_j_raon-2026-0042_ref_009","doi-asserted-by":"crossref","unstructured":"Li M, Yang C, Liu X, Yuan L, Zhang F, Wang M, et al. EphA3 promotes malignant transformation of colorectal epithelial cells by upregulating oncogenic pathways. Cancer Lett 2016; 383: 195-203. doi: 10.1016\/j.canlet.2016.10.004","DOI":"10.1016\/j.canlet.2016.10.004"},{"key":"2026090711002008813_j_raon-2026-0042_ref_010","doi-asserted-by":"crossref","unstructured":"Nasri B, Inokuchi M, Ishikawa T, Uetake H, Takagi Y, Otsuki S, et al. High expression of EphA3 (erythropoietin-producing hepatocellular a3) in gastric cancer is associated with metastasis and poor survival. BMC Clin Pathol 2017; 17: 8. doi: 10.1186\/s12907-017-0047-y","DOI":"10.1186\/s12907-017-0047-y"},{"key":"2026090711002008813_j_raon-2026-0042_ref_011","doi-asserted-by":"crossref","unstructured":"Surawska H, Ma PC, Salgia R. The role of ephrins and eph receptors in cancer. Cytokine Growth Factor Rev 2004; 15: 419-33. doi: 10.1016\/j.cytogfr.2004.09.002","DOI":"10.1016\/j.cytogfr.2004.09.002"},{"key":"2026090711002008813_j_raon-2026-0042_ref_012","doi-asserted-by":"crossref","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 2018; 34: i884-i90. doi: 10.1093\/bioinformatics\/bty560","DOI":"10.1093\/bioinformatics\/bty560"},{"key":"2026090711002008813_j_raon-2026-0042_ref_013","doi-asserted-by":"crossref","unstructured":"Kim D, Paggi JM, Park C, Bennett C, Salzberg SL. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat Biotechnol 2019; 37: 907-15. doi: 10.1038\/s41587-019-0201-4","DOI":"10.1038\/s41587-019-0201-4"},{"key":"2026090711002008813_j_raon-2026-0042_ref_014","doi-asserted-by":"crossref","unstructured":"Liao Y, Smyth GK, Shi W. Featurecounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014; 30: 923-30. doi: 10.1093\/bioinformatics\/btt656","DOI":"10.1093\/bioinformatics\/btt656"},{"key":"2026090711002008813_j_raon-2026-0042_ref_015","doi-asserted-by":"crossref","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550. doi: 10.1186\/s13059-014-0550-8","DOI":"10.1186\/s13059-014-0550-8"},{"key":"2026090711002008813_j_raon-2026-0042_ref_016","doi-asserted-by":"crossref","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. Clusterprofiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (N Y) 2021; 2: 100141. doi: 10.1016\/j.xinn.2021.100141","DOI":"10.1016\/j.xinn.2021.100141"},{"key":"2026090711002008813_j_raon-2026-0042_ref_017","doi-asserted-by":"crossref","unstructured":"Kanehisa M, Furumichi M, Sato Y, Matsuura Y, Ishiguro-Watanabe M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res 2025; 53: D672-D7. doi: 10.1093\/nar\/gkae909","DOI":"10.1093\/nar\/gkae909"},{"key":"2026090711002008813_j_raon-2026-0042_ref_018","doi-asserted-by":"crossref","unstructured":"Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30. doi: 10.1093\/nar\/28.1.27","DOI":"10.1093\/nar\/28.1.27"},{"key":"2026090711002008813_j_raon-2026-0042_ref_019","doi-asserted-by":"crossref","unstructured":"Park I, Lee H. EphB\/ephrinb signaling in cell adhesion and migration. Mol Cells 2015; 38: 14-9. doi: 10.14348\/molcells.2015.2116","DOI":"10.14348\/molcells.2015.2116"},{"key":"2026090711002008813_j_raon-2026-0042_ref_020","doi-asserted-by":"crossref","unstructured":"Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, et al. Roles of ephrinb ligands and EphB receptors in cardiovascular development: demarcation of arterial\/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 1999; 13: 295-306. doi: 10.1101\/gad.13.3.295","DOI":"10.1101\/gad.13.3.295"},{"key":"2026090711002008813_j_raon-2026-0042_ref_021","doi-asserted-by":"crossref","unstructured":"Anderton M, van der Meulen E, Blumenthal MJ, Schafer G. The role of the eph receptor family in tumorigenesis. Cancers (Basel) 2021; 13: 206. doi:10.3390\/cancers13020206","DOI":"10.3390\/cancers13020206"},{"key":"2026090711002008813_j_raon-2026-0042_ref_022","doi-asserted-by":"crossref","unstructured":"Chen J. Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv Cancer Res 2012: 114: 1-20. doi: 10.1016\/B978-0-12-386503-8.00001-6.","DOI":"10.1016\/B978-0-12-386503-8.00001-6"},{"key":"2026090711002008813_j_raon-2026-0042_ref_023","doi-asserted-by":"crossref","unstructured":"Kandouz M. The eph\/ephrin family in cancer metastasis: communication at the service of invasion. Cancer Metastasis Rev 2012; 31: 353-73. doi: 10.1007\/s10555-012-9352-1","DOI":"10.1007\/s10555-012-9352-1"},{"key":"2026090711002008813_j_raon-2026-0042_ref_024","doi-asserted-by":"crossref","unstructured":"Talia M, Cirillo F, Spinelli A, Zicarelli A, Scordamaglia D, Muglia L, et al. The ephrin tyrosine kinase A3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells. J Exp Clin Cancer Res 2023; 42: 122-64. doi: 10.1186\/s13046-023-02747-5","DOI":"10.1186\/s13046-023-02747-5"},{"key":"2026090711002008813_j_raon-2026-0042_ref_025","doi-asserted-by":"crossref","unstructured":"Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 2010; 10: 165-80. doi: 10.1038\/nrc2806","DOI":"10.1038\/nrc2806"},{"key":"2026090711002008813_j_raon-2026-0042_ref_026","doi-asserted-by":"crossref","unstructured":"Nievergall E, Lackmann M, Janes PW. Eph-dependent cell-cell adhesion and segregation in development and cancer. Cell Mol Life Sci 2012; 69: 1813-42. doi: 10.1007\/s00018-011-0900-6","DOI":"10.1007\/s00018-011-0900-6"},{"key":"2026090711002008813_j_raon-2026-0042_ref_027","doi-asserted-by":"crossref","unstructured":"Offenhauser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, et al. EphA3 pay-loaded antibody therapeutics for the treatment of glioblastoma. Cancers (Basel) 2018; 10: 519. doi: 10.3390\/cancers10120519","DOI":"10.3390\/cancers10120519"},{"key":"2026090711002008813_j_raon-2026-0042_ref_028","doi-asserted-by":"crossref","unstructured":"Wu Q, Suo Z, Risberg B, Karlsson MG, Villman K, Nesland JM. Expression of ephb2 and ephb4 in breast carcinoma. Pathol Oncol Res 2004; 10: 26-33. doi: 10.1007\/BF02893405","DOI":"10.1007\/BF02893405"},{"key":"2026090711002008813_j_raon-2026-0042_ref_029","doi-asserted-by":"crossref","unstructured":"Kumar SR, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley EJ, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol 2006; 169: 279-93. doi: 10.2353\/ajpath.2006.050889","DOI":"10.2353\/ajpath.2006.050889"},{"key":"2026090711002008813_j_raon-2026-0042_ref_030","doi-asserted-by":"crossref","unstructured":"Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JMM, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 2008; 118: 64-78. doi: 10.1172\/JCI33154","DOI":"10.1172\/JCI33154"},{"key":"2026090711002008813_j_raon-2026-0042_ref_031","doi-asserted-by":"crossref","unstructured":"Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. Retraction note: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004; 23: 1448-56. doi: 10.1038\/sj.onc.1207247","DOI":"10.1038\/sj.onc.1207247"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2026-0042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:00:47Z","timestamp":1788778847000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2026-0042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,7]]},"published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["10.2478\/raon-2026-0042"],"URL":"https:\/\/doi.org\/10.2478\/raon-2026-0042","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}